亚宝药业(600351.SH)签订中药新药项目技术转让协议

Core Viewpoint - The company has signed a technology transfer agreement for a new traditional Chinese medicine project, which is expected to enhance its R&D capabilities and competitiveness in the market [1] Group 1: Agreement Details - The company signed a technology transfer agreement with Shanxi Traditional Chinese Medicine Research Institute on August 4, 2025 [1] - The company acquired the clinical trial approval, patent rights, and related technical materials for the traditional Chinese medicine new drug "Chaiqin Ning Shen Granules" for RMB 22 million [1] Group 2: Strategic Implications - The acquisition of the clinical trial approval and patent rights is expected to facilitate the rapid expansion of the company's traditional Chinese medicine R&D pipeline [1] - This move aligns with the company's development strategy and is in the interest of all shareholders [1] Group 3: Impact on Financial Performance - The agreement's implementation timeline is lengthy, and it is noted that there will be no significant short-term impact on the company's operating performance [1]